Alise Reicin

Chief Executive Officer, Tectonic Therapeutic

Search every verified Alise Reicin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Alise Reicin, Chief Executive Officer of Tectonic Therapeutic, participated in the USAIC's Oncology Panel on May 2, 2023, where she discussed topics related to cellular therapy and treatment access. During the panel, Reicin expressed optimism about the early stages of cellular therapy, citing a recent press release on a TCR approach to solid tumors with a response rate over 60%, while noting uncertainty about durability. She also addressed the challenge of democratizing access to medicines, stating that moving from autologous to allogeneic or NK cell therapies is the primary way to significantly reduce manufacturing costs, and mentioned in vivo approaches as another potential cost-reduction avenue, though she noted that using lentiviruses for in vivo therapies still carries manufacturing expenses.